>This apart from the obvious synergies there are by bringing all transgenics IP under one roof.<
The combination does make sense from a business standpoint, but there is the nagging matter of valuation. Would GTC would accept an equity stake in a combined Pharming-GTC that merely mirrored the relative valuations of the two companies in the stock market? I highly doubt it!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”